CSO Leadership Series: Tony Coyle, CSO, Pfizer Centers for Therapeutic Innovation
Wednesday, October 15, 2014 from 8:30 AM to 10:00 AM (EDT)
New York, NY
San Francisco, California
London, United Kingdom
October 15, 2014
Anthony Coyle, PhD
Vice President and Chief Scientific Officer
Pfizer Centers for Therapeutic Innovation
Anthony “Tony” Coyle is Vice President and Chief Scientific Officer of the Centers for Therapeutic Innovation (CTI) based out of Boston. CTI was established in late 2010 as a new model to drive innovation in BioTherapeutics R & D. Tony is responsible for the CTI sites, which currently include CTI – New York City, CTI- Boston and CTI-California. Tony is supported by his leadership team, which includes the site heads of each CTI, his operations team and project management.
As a former Vice President and Global Head of Respiratory, Inflammation, and Autoimmunity Research at Medimmune Biologics, a Division of AstraZeneca, Tony has advanced a biologic portfolio from discovery to Phase Two in the areas of Respiratory and Autoimmune diseases including Lupus, Asthma and COPD. Prior to joining Medimmune, Tony was Director of Research at Millennium Pharmaceuticals, where he led a group responsible for the identification of novel target genes as well as for late stage lead optimization and delivery of both small molecule and biologic development candidates.
About the CSO Leadership Series
Chief Science Officers and Chief Medical Officers have a tough job—organizing and managing R&D uncovering new disruptive discovery and development models; assessing the impact of pricing, reimbursement, and regulation—all while raising capital, working with investors, and strategizing appropriate exits.
NewYorkBIO’s CSO Leadership Series is designed to help bioscience CSO/CMOs to engage with experienced industry leaders and address the unique challenges associated with the job. Attendees will gain guidance on strategic planning, exit planning, and insight into the trends affecting the future of medical research in the emerging life science space.
Limited to 25 attendees, the CSO Leadership Series is restricted to life science executives (no service providers beyond the sponsor) and will offer a unique opportunity to hear directly from—and to network with—New York’s life science leadership.
Exclusive CEO Leadership Series Sponsor
WATCH FOR UPCOMING DATES FOR THESE SPEAKERS
George Yancopoulos, MD, PhD
Founding Scientist, President, Regeneron Laboratories
Chief Scientific Officer, Regeneron
George D. Yancopoulos, M.D., Ph.D., joined Regeneron in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's three FDA-approved drugs - including EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of its foundation technologies including the TRAP technology, VelociGene®, and VelocImmune®.
More to come!